FDA And FTC Join Forces On Biosimilars
Teaming Up To Eliminate Barriers To Biosimilar Competition
Two agencies to take action against false or misleading communications about biosimilars, impediments to sampling, and anticompetitive patent settlement agreements; to hold public workshop in March.
